|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Colestipol]] |
| {{colestipol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use.
| |
| | |
| COLESTID Granules and FLAVORED COLESTID Granules are indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (LDL) cholesterol in patients with primary [[hypercholesterolemia]] (elevated low density lipoproteins [LDL] cholesterol) who do not respond adequately to diet. Generally, COLESTID and FLAVORED COLESTID have no clinically significant effect on serum triglycerides, but with its use triglyceride levels may be raised in some patients.
| |
| | |
| Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to [[hypercholesterolemia]]. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD.
| |
| | |
| According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below.
| |
| | |
| {|
| |
| |-
| |
| |[[File:COLESTIPOl 01.jpg|thumb|800px]]
| |
| |-
| |
| |}<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = COLESTID (COLESTIPOL HYDROCHLORIDE) GRANULE, FOR SUSPENSION FLAVORED COLESTID (COLESTIPOL HYDROCHLORIDE) GRANULE, FOR SUSPENSION [PHARMACIA AND UPJOHN COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21b37725-fc0c-4365-a7dc-1a473d42502d | publisher = | date = | accessdate = 11 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| {{Lipid modifying agents}}
| |
| | |
| [[Category:Bile acid sequestrants]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |